AMEH

ANALYST NOTE: AMEH (Apollo Medical Holdings, Inc.) Date: 2026-06-13 Current Price: $40.82

1. Structural Readiness

State: Forming Aggressive/Pre-Breakout Entry: — (Not actionable on forming structure alone) Breakout Level: — (Pending confirmation of the structural high) Current Price: $40.82 Extension: — (No confirmed breakout to measure extension against) ATR Current: 4.0% (High)

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Thesis: None named at this date. Assessment: This is a tactical, setup-led name. There is no named macro or secular thesis attached to this specific setup at the time of writing. The conviction must be derived strictly from the quality of the technical setup (the forming coil) and the underlying business fundamentals as reported in the most recent earnings data. No external narrative should be invented to support the trade; the trade is on the structure and the verified financials.

3. Business Overview

Company: Apollo Medical Holdings, Inc. (AMEH) Industry: Healthcare Technology / Integrated Care Delivery Business Model: AMEH operates as a technology-driven healthcare firm that centers operations around medical practitioners to deliver comprehensive healthcare solutions. The company utilizes a proprietary platform for population health management and care provisioning, running an integrated, value-focused healthcare model. It provides meticulously coordinated care for patients, general practitioners, specialists, acute care facilities, and health insurance providers.

Key Fundamentals (Source: Q1 2026 Earnings Transcript, 2026-05-07):

• Revenue Growth: Astrana (a key operating segment) delivered revenue of $965.1 million in Q1 2026, up 56% year-over-year.
• Profitability: Adjusted EBITDA for the segment reached $66.3 million, up 82% year-over-year.
• Guidance (Management Expectations): Management expects total revenue for the full year to be in the range of $3.8 billion to $4.1 billion, with adjusted EBITDA between $250 million and $280 million, and free cash flow between $105 million and $132.5 million.
• Value-Based Care Penetration: At quarter end, approximately 80% of care partners' revenue and 40% of owned membership were in full risk arrangements.
• Member Base: The company ended the quarter serving approximately 1.55 million members in value-based care arrangements.
• Operational Efficiency: Providers actively using the platform achieve a 24% higher gap closure rate and a 30% higher annual wellness visit completion rate.
• Balance Sheet: Net leverage on a pro forma basis was approximately 2.3x, down from 2.6x at year-end, reflecting strong free cash flow generation.
• Historical Growth: Management notes that from 2019 through the 2026 guidance, the company has grown revenue at approximately a 32% CAGR and adjusted EBITDA at a 25% CAGR.

4. Archetype and Conviction

Archetype: Growth Leader Fit: The name fits the "Growth Leader" archetype due to the demonstrated 32% revenue CAGR and 25% EBITDA CAGR over the 2019-2026 period, coupled with accelerating Q1 2026 growth (56% revenue, 82% EBITDA). The business model is shifting toward higher-value, full-risk arrangements (80% of care partner revenue), which typically supports margin expansion and operating leverage.

Valuation Context:

• Forward Consensus EPS (FY1): $2.47 (Financial Spine coverage complete).
• Implied Multiple: At a current price of $40.82, the stock trades at approximately 16.5x forward consensus EPS.

Conviction Stack:

• Thesis Strength: Low (Tactical only; no macro thesis).
• Evidence Quality: High. The earnings transcript provides robust, specific data points on revenue, EBITDA, leverage, and operational metrics.
• Structural Quality: Moderate. The ATR is 4.0% (High), which is within the historical "sweet spot" (4–6%) for volatility, suggesting sufficient liquidity and interest, but the setup is still "Forming" rather than "Confirmed."
• Rerating Potential: Moderate to High. The combination of accelerating growth, deleveraging (2.6x to 2.3x), and strong FCF generation supports a potential multiple expansion if the breakout confirms.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Management raising full-year guidance beyond the current $3.8B–$4.1B revenue range.
• Further reduction in net leverage below 2.0x.

What Would Invalidate the Case:

• A significant miss on the Q2 2026 revenue or EBITDA guidance relative to the current trajectory.
• A spike in net leverage that contradicts the deleveraging trend.

Gaps in Evidence:

• Breakout Confirmation: There is no evidence of a breakout having occurred yet; the setup is strictly "forming."
• Sector Classification: The specific sector and industry labels are missing from the provided data cache, though the business description clearly places it in Healthcare Technology/Services.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Q1 2026 revenue up 56% YoY to $965.1M; Adjusted EBITDA up 82% YoY to $66.3M; Net leverage reduced to 2.3x from 2.6x; 80% of care partner revenue in full risk arrangements. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" status and lack of confirmed entry trigger. Expected path: Management expects continued revenue growth in the $3.8B-$4.1B range with FCF generation of $105M-$132.5M; structural implications suggest margin expansion as value-based care penetration increases. Expected horizon: 3 to 6 months for the forming coil to resolve into a confirmed breakout or invalidation.